PanamaTuberculosis profile
Population  2017 4.1 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (0.21–0.25) 5.6 (5.1–6)
Mortality (HIV+TB only) 0.083 (0.059–0.11) 2 (1.4–2.7)
Incidence  (includes HIV+TB) 2.2 (1.7–2.8) 54 (42–69)
Incidence (HIV+TB only) 0.4 (0.31–0.51) 9.8 (7.5–12)
Incidence (MDR/RR-TB)** 0.084 (0.036–0.15) 2 (0.87–3.7)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.11 (0.1–0.12) 0.62 (0.54–0.7) 0.73 (0.63–0.84)
Males 0.14 (0.13–0.15) 1.4 (1.1–1.6) 1.5 (1.2–1.8)
Total 0.25 (0.23–0.27) 2 (1.5–2.4) 2.2 (1.7–2.8)
TB case notifications, 2017  
Total cases notified 1 867
Total new and relapse 1 778
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 95%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 65%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.14 (0.11–0.18)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 292 17%
          - on antiretroviral therapy 292 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  66
(33–99)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.79–4.5) 17% (8.9–29)  
% notified tested for rifampicin resistance 19% 21% 557
MDR/RR-TB cases tested for resistance to second-line drugs   34
Laboratory-confirmed cases MDR/RR-TB: 53, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 50, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 81% 1 810
Previously treated cases, excluding relapse, registered in 2016 54% 78
HIV-positive TB cases registered in 2016 62% 269
MDR/RR-TB cases started on second-line treatment in 2015 29% 28
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 11%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 1.9
Funding source: 6% domestic, 44% international, 50% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data